Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 9,639 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Recurrent Clear all
Completed Phase 1 Interventional

A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas

NCT04089449
View directory record Official record
Conditions
Advanced Solid Tumor, Recurrent Glioma
Interventions
PRT811
Drug
Lead sponsor
Prelude Therapeutics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
Denver, Colorado • New Haven, Connecticut • Newark, Delaware + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 1 Interventional Results available

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

NCT03229278
View directory record Official record
Conditions
Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer, Recurrent Bladder Carcinoma, Recurrent Classical Hodgkin Lymphoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Renal Cell Carcinoma, Stage III Bladder Cancer, Stage III Lymphoma, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage III Renal Cell Cancer, Stage III Skin Melanoma, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Skin Melanoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Lymphoma, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Solid Neoplasm
Interventions
Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 17, 2026, 5:56 PM EDT
Not listed Phase 3 Interventional

Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma

NCT00022685
View directory record Official record
Conditions
Lymphoma
Interventions
epratuzumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available

Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma

NCT01583543
View directory record Official record
Conditions
Ewing's Sarcoma
Interventions
Olaparib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00334776
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
MART-1 antigen, gp100:209-217(210M) peptide vaccine, therapeutic autologous dendritic cells, tyrosinase peptide
Biological
Lead sponsor
University of Southern California
Other
Eligibility
16 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
2
States / cities
Los Angeles, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 17, 2026, 5:56 PM EDT
Active, not recruiting Not applicable Interventional

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

NCT05455606
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Interventions
Best Practice, Chart Abstraction, Educational Intervention, Genomic Profile, Interview, Questionnaire Administration, Tumor Board Review
Other · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
70
States / cities
Phoenix, Arizona • Savannah, Georgia • Honolulu, Hawaii + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Women With Metastatic Breast Cancer

NCT00003184
View directory record Official record
Conditions
Breast Cancer
Interventions
BCG vaccine, CD80 breast cancer vaccine, sargramostim
Biological
Lead sponsor
Providence Cancer Center, Earle A. Chiles Research Institute
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 1 Interventional

Phase 1 of EC1169 In Patients With Recurrent MCRPC

NCT02202447
View directory record Official record
Conditions
Prostate Cancer
Interventions
EC1169, EC0652
Drug · Other
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Scottsdale, Arizona • New Haven, Connecticut • New Orleans, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 17, 2026, 5:56 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer

NCT02874885
View directory record Official record
Conditions
Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Rectosigmoid Adenocarcinoma, Recurrent Rectal Adenocarcinoma, Recurrent Rectosigmoid Carcinoma, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8
Interventions
Biospecimen Collection
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder

NCT00054340
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, methotrexate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2010 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 1 Interventional

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

NCT02332850
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Carfilzomib, Dexamethasone
Biological · Drug
Lead sponsor
Thomas Martin, MD
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
5
States / cities
San Francisco, California • Denver, Colorado • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

Occipital Blocks for Acute Migraine

NCT03526874
View directory record Official record
Conditions
Chronic Migraine, Headache, Episodic Migraine
Interventions
Lidocaine 4% Topical Application Cream [LMX 4], Lidocaine Hydrochloride 2 mg/mL Injectable Solution, Normal Saline
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
7 Years to 21 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 2 Interventional

Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer

NCT00010218
View directory record Official record
Conditions
Lung Cancer
Interventions
karenitecin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
44
States / cities
La Jolla, California • San Francisco, California • Wilmington, Delaware + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 1 Interventional

Phase I: At-Home Support for Rural Women Using Group Video Calling

NCT01672684
View directory record Official record
Conditions
Depression, Post-traumatic Stress Disorder, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
support group therapy, educational intervention
Procedure · Other
Lead sponsor
Stanford University
Other
Eligibility
21 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Nevada City, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2014 · Synced Oct 17, 2026, 5:56 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

NCT03502733
View directory record Official record
Conditions
Lymphoma, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Bethesda, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 17, 2026, 5:56 PM EDT
Terminated Phase 1 Interventional

Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer

NCT00088933
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Recurrent Colon Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Rectal Cancer, Recurrent Small Cell Lung Cancer, Stage IV Colon Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Rectal Cancer
Interventions
recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)-TRICOM vaccine, docetaxel, sargramostim
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 17, 2026, 5:56 PM EDT
Terminated Not applicable Interventional

Ketogenic Diet in Children With Malignant or Recurrent/Refractory Brain Tumor

NCT03328858
View directory record Official record
Conditions
Brain Tumors
Interventions
Ketogenic Diet
Other
Lead sponsor
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Other
Eligibility
12 Months to 35 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 17, 2026, 5:56 PM EDT
Terminated Early Phase 1 Interventional

Study of Sonodynamic Therapy in Participants With Recurrent High-Grade Glioma

NCT04559685
View directory record Official record
Conditions
High Grade Glioma
Interventions
SONALA-001(ALA) and MR-Guided Focused Ultrasound device (MRgFUS), MR-Guided Focused Ultrasound device (MRgFUS)
Combination Product · Device
Lead sponsor
Nader Sanai
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 2 Interventional

Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia

NCT00002704
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, asparaginase, cyclophosphamide, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, liposomal cytarabine, mercaptopurine, mesna, methotrexate, therapeutic hydrocortisone, thiotepa, vincristine sulfate, low-LET electron therapy, low-LET photon therapy
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 20 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
62
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21

NCT00583752
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
Adenovirus/PSA Vaccine
Biological
Lead sponsor
David M Lubaroff
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 2 Interventional

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

NCT03732352
View directory record Official record
Conditions
EGFR Gene Amplification, EGFR Gene Mutation, Glioblastoma, Recurrent Glioblastoma, Supratentorial Glioblastoma, TP53 Wt Allele
Interventions
Fludeoxyglucose F-18, Osimertinib, Positron Emission Tomography
Other · Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 1 Interventional

Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors

NCT01017640
View directory record Official record
Conditions
Solid Neoplasm
Interventions
Laboratory Biomarker Analysis, Mitomycin, Veliparib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
2
States / cities
Georgetown, Kentucky • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Phase 3 Interventional

Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic

NCT00003440
View directory record Official record
Conditions
HER2-negative Breast Cancer, HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
paclitaxel, trastuzumab, quality-of-life assessment, laboratory biomarker analysis
Drug · Biological · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 17, 2026, 5:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Laboratory Model for Relapse to Sedentary Behavior

NCT04161040
View directory record Official record
Conditions
Exercise
Interventions
Performance-based incentives
Behavioral
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 74 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 17, 2026, 5:56 PM EDT